Compare MATW & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | PRME |
|---|---|---|
| Founded | 1850 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.1M | 553.2M |
| IPO Year | 1995 | 2022 |
| Metric | MATW | PRME |
|---|---|---|
| Price | $21.02 | $3.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.56 |
| AVG Volume (30 Days) | 781.0K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,795,737,000.00 | $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $20.87 | $2.67 |
| 52 Week High | $30.93 | $6.94 |
| Indicator | MATW | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 58.44 |
| Support Level | N/A | $3.16 |
| Resistance Level | $27.73 | $3.68 |
| Average True Range (ATR) | 0.82 | 0.22 |
| MACD | -0.14 | 0.06 |
| Stochastic Oscillator | 8.86 | 89.58 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.